Rocket Pharmaceuticals, Inc.RCKT
Price (close)
$2.69
Market cap
$295.3M
P/E
—
Revenue (TTM)
$0
Net income
-$17.3M
Dividend yield
—
1-year total return
-15.7%
Net margin
—
Revenue growth
—
Debt / equity
—
What Rocket Pharmaceuticals, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$139.7M | -$169.1M | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
| Free cash flow | -$95.2M | -$128.8M | -$186.5M | -$211.4M | -$215.6M | -$190.5M |
More on RCKT.
- Rocket Pharmaceuticals, Inc. summary
- Rocket Pharmaceuticals, Inc. financial statements
- Rocket Pharmaceuticals, Inc. key metrics
- Rocket Pharmaceuticals, Inc. health scores and style box
- Rocket Pharmaceuticals, Inc. earnings
- Rocket Pharmaceuticals, Inc. dividends
- Rocket Pharmaceuticals, Inc. valuation
- Rocket Pharmaceuticals, Inc. ownership and insiders
- Rocket Pharmaceuticals, Inc. peers
Figures from Rocket Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.